10/7/2013 10:44:10 AM
EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company primarily focused on developing innovative products for skin diseases and conditions, today announced that the underwriters for its recently announced public offering of common stock partially exercised their over-allotment option to purchase an additional 1,311,698 shares of common stock at a public offering price of $4.10 per share. The partial exercise of the over-allotment option increases the aggregate net proceeds to the company, after underwriting discounts and commissions and estimated offering expenses, from approximately $42.1 million to approximately $47.2 million. The closing of the sale of the additional shares is expected to occur on October 9, 2013, subject to satisfaction of customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
comments powered by